On Friday, Maxwell Technologies Inc. (NASDAQ:MXWL)’s shares declined -11.84% to $6.33.
Maxwell Technologies Inc. (MXWL) stated revenue of $34.7 million for its first quarter ended March 31, 2015, down 25 percent from the $46.0 million recorded in the first quarter of 2014.
First quarter ultra capacitor revenue was down 31 percent contrast with the $32.0 million recorded in the first quarter of 2014. Sales of high voltage capacitor and microelectronics products totaled $12.7 million in Q115, down 9 percent from the $14.0 million recorded in Q114.
Maxwell Technologies, Inc., together with its auxiliaries, develops, manufactures, and markets energy storage and power delivery products worldwide.
Emerge Energy Services LP (NYSE:EMES)’s shares dropped -11.76% to $44.65.
Emerge Energy Services LP (EMES) declared that the board of directors of its general partner has declared a cash distribution of $1.00 for the first quarter of 2015. This distribution represents a 29% decrease contrast to the fourth quarter 2014 distribution of $1.41 per unit and a 12% decrease contrast to the first quarter 2014 distribution of $1.13 per unit. The distribution will be paid on May 14, 2015 to all unitholders of record as of May 6, 2015.
Emerge Energy Services LP acquires, owns, operates, and develops a portfolio of energy service assets in the United States. The company operates in two segments, Sand and Fuel. The Sand segment is involved in the production and sale of various grades of industrial sand primarily used in the extraction of oil and natural gas, in addition to in the production of building products and foundry materials.
At the end of Friday’s trade, Great Basin Scientific Inc (NASDAQ:GBSN)‘s shares dipped -1.28% to $4.17.
Great Basin Scientific Inc (GBSN) declared that the U.S. Food and Drug Administration (FDA) has granted clearance for its molecular diagnostic test for Group B Streptococcus (GBS). This is Great Basin’s second assay to be cleared by the FDA. The Company’s first test, for Clostridium difficile, or C. diff, was approved in May 2012. Great Basin plans to launch the GBS assay commercially in the second quarter of 2015.
Great Basin Scientific, Inc., a molecular diagnostic testing company, doing business as Great Basin Corporation, develops and commercializes molecular diagnostic systems that are designed to test hospital-attained infections.
ResMed Inc. (NYSE:RMD), ended its Friday’s trading session with -10.47% loss, and closed at $65.70.
ResMed Inc. (RMD) declared results for its quarter ended March 31, 2015. Revenue for the quarter was $422.5 million, a 6 percent enhance contrast to the quarter ended March 31, 2014 (a 13 percent enhance on a constant currency basis). Net income was $91.0 million, an enhance of 1 percent contrast to the quarter ended March 31, 2014. Diluted earnings per share for the quarter were $0.64, an enhance of 2 percent contrast to the quarter ended March 31, 2014. Non-GAAP diluted earnings per share for the quarter were $0.65, a 2 percent enhance contrast to the quarter ended March 31, 2014.
ResMed Inc. develops, manufactures, distributes, and markets medical equipment for the diagnosis, treatment, and administration of respiratory disorders, with a focus on sleep-disordered breathing. Its products portfolio comprises airflow generators, diagnostic products, mask systems, motors, and headgear, in addition to other accessories, such as cold passover humidifiers, carry bags, and breathing circuits; and humidifiers comprising H5i and H4i, which connect with the continuous and variable positive airway pressure, and AutoSet flow generators to humidify and heat the air delivered to the patient to prevent the drying of nasal passages.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
